Biomarkers for lupus nephritis: The quest continues

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 11, 2009, Pages 1858-1865

  Rovin, Brad H ^a   Zhang, Xiaolan ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BIOLOGICAL MARKER; CERULOPLASMIN; CHEMOKINE; COMPLEMENT COMPONENT C1Q ANTIBODY; ENDOTHELIAL PROTEIN C RECEPTOR; FATTY ACID BINDING PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPCIDIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OROSOMUCOID; TRANSCRIPTION FACTOR FOXP3; TRANSFERRIN;

CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; OUTCOMES RESEARCH; PREDICTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN URINE LEVEL; SHORT SURVEY; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

BIOLOGICAL MARKERS; HUMANS; KIDNEY FAILURE; LUPUS NEPHRITIS; PREDICTIVE VALUE OF TESTS;

EID: 73349132285     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03530509     Document Type: Short Survey

References (63)

1. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon JP, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219-2228, 2005
2. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, Group ALMS: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112, 2009
3. Bao H, Liu Z-H, Xie H-L, Hu W-X, Zhang H-T, Li L-S: Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19: 2001-2010 2008
4. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980, 2004
5. Ioannidis JPA, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos M: Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57: 258-264, 2000
6. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K: Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann Rheum Dis 62: 435-439, 2003
7. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns J-P, Crevera R: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 50: 3934-3940, 2004
8. Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA: Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis 65: 187-193, 2007
9. Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A, Vecchi ML, Messa P, Sinico RA: Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 68: 234-237, 2009
10. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE: Routine immunologic tests in systemic lupus erythematosus: Is there a need for more studies? J Rheumatol 23: 1891-1896, 1996
11. Esdaile JM, Abrahamowicz M, Joseph L, Mackenzie T, Li Y, Danoff D: Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Arthritis Rheum 39: 370-378, 1996
12. Coremans IEM, Spronk PE, Bootsma H, Daha MR, van der Voort EAM, Kater L, Breedveld FC, Kallenberg CG: Changes in antibodies to C1q predict renal relapse in system lupus erythematosus. Am J Kidney Dis 26: 595-601, 1995
13. Ho A, Barr SG, Magder LS, Petri M: A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 44: 2350-2367, 2001
14. Ho A, Magder LS, Barr SG, Petri M: Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 44: 2342-2349, 2001
15. Rovin BH: The chemokine network in systemic lupus erythematosis nephritis. Frontiers Biosci 13: 904-922, 2007
16. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu C-Y, Nagaraja HN: Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16: 467-473, 2005
17. Chan RW-Y, Lai FM-M, Li EK-M, Tam L-S, Wong TY-H, Szeto CYK, Li PK-T, Szeto C-C: Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 50: 2882-2890, 2004
18. Chan RW-Y, Lai FM-M, Li EK-M, Tam L-S, Chow K-M, Li PK-T, Szeto C-C: Messenger RNA expression of RANTES in the urinary sediment of pateints with lupus nephritis. Nephrology 11: 219-225, 2006
19. Chan RW-Y, Lai FM-M, Li EK-M, Tam L-S, Chow K-M, Li PK-T, Szeto C-C: The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol Dial Transplant 21: 1534-1540, 2006
20. Avihingsanon Y, Phumesin P, Benjachat T, Akkasilpa S, Kittikowit V, Praditpornsilpa K, Wongpiyabavorn J, Eiam-Ong S, Hemachudha T, Tungsanga K, Hirankarn N: Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis. Kidney Int 69: 747-753, 2006
21. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor B1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 271: 17779-17784, 1996
22. Sakai N, Wada T, Furuichi K, Shimizu K, Kokubo S, Hara A, Yamahana J, Okumura T, Matsushima K, Yokoyama H, Kaneko S: MCP-1/CCL2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. J Leukocyte Biol 79: 555-563, 2006
23. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, Camussi G, Gruden G: Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 51: 198-207, 2008
24. Wada T, Furuichi K, Segawa-Takeada C, Shimizu M, Sakai N, Takeda S-I, Takasawa K, Kida H, Kobayashi K-I, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H: MIP-1a and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56: 995-1003, 1999
25. Rovin BH: Chemokines as therapeutic targets in renal inflammation. Am J Kid Dis 34: 761-764, 1999
26. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18: 407-413, 2007
27. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, Syed H, Ali S, Barasch J, Devarajan P: Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 3: 665-673, 2008
28. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte DP, Grom A, Mishra J, Devarajan P: Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 54: 2577-2584, 2006
29. Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, Putterman C: Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 56: 1894-1903, 2007
30. Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, Haines KA, Onei K, O'Neil K, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI: Neutorphil gelatinase-associated lipocalin (NGAL) anticipates the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009, in press
31. Suzuki M, Ross GF, Wiers K, Nelson S, Bennett M, Passo MH, Devarajan P, Brunner HI: Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol 22: 2047-2057, 2007
32. SuzuKi M, Wiers K, Brooks EB, Greis KD, Haines KA, Klein-Gitelman M, Olson J, Onel KB, Oneil KM, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI: Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res 65: 530-536, 2009
33. Djeha A, Perez-Arellano JL, Hayes SL, Oria R, Simpson RJ, Raja KB, Brock JH: Cytokine-mediated regulation of transferrin synthesis in mouse macrophages and human T lymphocytes. Blood 85: 1036-1042, 1995
34. Ryu SY, Jeong KS, Kang BN, Park SJ, Yoon WK, Kim SH, Kim TH: Modulation of transferrrin synthesis, transferrin receptor expression, iNOS expression, and NO production in mouse macrophages by cytokines, either alone or in combination. Anticancer Res 20: 3331-3338, 2000
35. Chan RW-Y, Tam L-S, Li EK-M, Lai FM-M, Chow K-M, Lai K-B, Li PK-T, Szeto C-C: Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 48: 1326-1331, 2003
36. Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja HN, Birmingham DJ, Yu CY, Hebert LA, Rovin BH: Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 74: 799-807, 2008
37. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271-1276, 2004
38. Andrews NC: Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 113: 1251-1253, 2004
39. Lee P, Peng H, Gelbart T, Wang L, Beutler E: Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 102: 1906-1910, 2005
40. Tackey E, Lipsky PE, Illei GG: Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13: 339-343, 2004
41. Mongan AE, Ramdahin S, Warrington RJ: Interleukin-10 response abnormalities in systemic lupus erythematosus. Scand J Immunol 46: 406-412, 1997
42. Aringer M, Smolen JS: Cytokine expression in lupus kidneys. Lupus 14: 13-18, 2005
43. Siegert CEH, Daha MR, Tseng CMES, Coremans IEM, van Es LA, Breedveld FC: Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 52: 851-856, 1993
44. Oelzner P, Deliyska B, Funfstuck R, Hein G, Herrmann D, Stein G: Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus-relationship with disease activity and renal involvement. Clin Rheumatol 22: 271-278, 2003
45. Marto N, Bertolaccini ML, Calabuig E, Hughes GRV, Khamashta MA: Anti-C1q antibodies in nephritis: Correlation between titers and renal disease activity and positive predictive vale in system lupus erythematosus. Ann Rheum Dis 64: 444-448, 2005
46. Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, Testoni C, Tincani A, Banfi G, Balestrieri G, Schifferli JA, Meroni PL, Ponticelli C: Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37: 490-498, 2001
47. Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli JA: Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 42: 187-188, 1999
48. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K: Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 284: 175-182, 2006
49. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Kikawa A, Hirano N, Hirata Y, Goto A, Omata M: Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 143: 23-30, 2004
50. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto H, Mise N, Kimura K: Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial. J Lab Clin Med 145: 125-133, 2005
51. Rovin BH, McKinley A, Song H, Prosek J: Urine liver-fatty acid binding protein in patients with systemic lupus erythematosus. J Am Soc Nephrol 19: 776A, 2008
52. Ye X, Fukudome K, Tsuneyoshi N, Satoh T, Tokunaga O, Sugawara K, Mizokami H, Kimoto M: The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries. Biochem Biophys Res Commun 259: 671-677, 1999
53. Sesin CA, Yin X, Esmon CT, Buyon JP, Clancy RM: Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: In vivo and in vitro evidence. Kidney Int 68: 110-120, 2005
54. Izmirly PM, Barisoni L, Buyon JP, Kim MY, Rivera TL, Schwartzman JS, Weisstuch JM, Liu DT, Bernstein S, Tseng CE, Belmont HM, Esmon CT, Merrill JT, Askanase AD, Thomas DB, Clancy RM: Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxf) 48: 513-519, 2009
55. Banham AH, Powrie FM, Suri-Payer E: FOXP3+ regulatory T cells: Current controversies and future perspectives. Eur J Immunol 36: 2832-2836, 2006
56. Valencia X, Yarboro C, Illei GG, Lipsky PE: Deficient CD4+CD25high T regulatory cell function in pateints with active systemic lupus erythematosus. J Immunol 178: 2579-2588, 2007
57. Wang G, Lai FM, Tam LS, Li EK, Kwan BC, Chow KM, Li PK, Szeto CC: Urinary FOXP3 mRNA in patients with lupus nephritis - relation with disease activity and treatment response. Rheumatology (Oxf) 48: 755-760, 2009
58. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, Arthur JM: Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 18: 913-922, 2007
59. Oates JC, Varghese S, Bland AM, Taylor TP, Self SE, Stanislaus R, Almeida JS, Arthur JM: Prediction of urinary protein markers in lupus nephritis. Kidney Int 68: 2588-2592, 2005
60. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW: Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 3: 2274-2284, 2006
61. Amoura Z, Combadiere C, Faure S, Parizot C, Miyara M, Raphael D, Ghillani P, Debre P, Piette J-C, Gorochov G: Roles of CCR1 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum 48: 3487-3496, 2003
62. Narumi S, Takeuchi T, Kobayashi Y, Konishi K: Serum levels of ifn-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12: 1561-1565, 2000
63. Nakayamada S, Saito K, Nakano K, Tanaka Y: Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 56: 1559-1568, 2007